Origin of chronic lymphatic leukaemia: lead discovered

Origin of chronic lymphatic leukaemia: lead discovered

Up until now the causes of the development of chronic lymphatic leukaemia, the most common form of cancer of the blood in Europe, have been unknown. At present a cure is not possible. A research group at the MedUni Vienna led by Christoph Steininger of the University Department of Internal Medicine I has now however discovered a lead on the origin of this disease. Says Steiniger: "This could influence the therapy approach taken in treating chronic lymphatic leukaemia."

For approximately 20 years it has been suspected that chronic lymphatic leukaemia occurs through the stimulation of with other factors also playing a part. In the current research study, which has been published in the journal Blood, the scientists were looking for an antigen that attaches itself to the leukaemia and they were able to identify the protein pUL32 of the human cytomegalovirus.

Virus "conceals" itself in cells

The cytomegalovirus, a member of the herpes family of viruses, is carried by approximately 60 to 70 percent of the Austrian population without them getting ill from it and without them even noticing that they are carrying the virus. In most cases people are infected with the virus during childhood. After being infected, the virus goes on to survive in the cells of the immune system their whole life long. The virus conceals itself within the cells and in addition it confuses the immune system with its own .

Only when the immune system in an infected person is weakened, for example by medical suppression as part of an organ transplant or in an HIV-illness, can the virus make someone ill. Whether this can trigger leukaemia, or whether the connection observed between leukaemia and the cytomegalovirus points to another mechanism, independent of the virus, in the origin of the cancer is now the subject of several follow-up studies.

One of the follow-up studies is looking at whether an against the cytomegalovirus can prevent the leukaemia cells from being stimulated and so prevent the further advance of the disease.

More information: „Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus an B-cell superantigen.” C. Steininger, et al. Kipps. Bloodjournal, doi: 10.1182/bllod-2011-08-374058

Provided by Medical University of Vienna

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Gene clue to how virus causes cancer

Mar 19, 2012

Virologists and immunologists at Imperial College London and University of Zurich have identified mutations in Epstein-Barr virus (EBV) that increase the capacity of the virus to cause cancer, in a study published ...

Virus a potential future cancer medicine

Sep 16, 2011

In a new project, researchers from LIFE – the Faculty of Life Sciences at the University of Copenhagen – document that the vesicular stomatitis virus (VSV) plays a previously unknown dual role in the prevention ...

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

14 hours ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

User comments